title: Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
authors.forename: R Andrew
authors.initials: RA
authors.lastname: Seaton
authors.forename: Ray
authors.initials: R
authors.lastname: Fox
authors.forename: Neena
authors.initials: N
authors.lastname: Bodasing
authors.forename: S Erica
authors.initials: SE
authors.lastname: Peters
authors.forename: Ysobel
authors.initials: Y
authors.lastname: Gourlay
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D015215:Zidovudine; D000099227:Abacavir